Latest news with #neuroimaging
Yahoo
02-07-2025
- Health
- Yahoo
From Crisis to Cure: Capitalizing on the Urgent Need for Scalable Traumatic Brain Injury Treatment Care Solutions Says Astute Analytica
The global traumatic brain injury (TBI) treatment market is undergoing a significant transformation, fueled by rising global incidence rates, expanding awareness about brain health, and accelerating innovation in diagnostics and therapeutics. TBI, defined as damage to the brain caused by external mechanical force such as blows, jolts, or penetrative injuries, remains one of the most pressing neurological public health concerns worldwide. It stems from various causes, including falls, road traffic accidents (RTAs), sports-related injuries, assaults, and gunshot wounds. The burden of TBI spans across demographics, with elderly populations predominantly affected by falls, young adults and working-age groups disproportionately impacted by vehicular accidents, and youth increasingly suffering from sports-related TBIs. Chicago, July 02, 2025 (GLOBE NEWSWIRE) -- The global traumatic brain injury market (TBI) treatment market is projected to grow from USD 2.5 billion in 2024 to USD 4.7 billion by 2033, reflecting a robust compound annual growth rate (CAGR) of 7.2% during the forecast period. This expansion is supported by several market forces, including technological advances in neuroimaging and minimally invasive diagnostics, government-backed research initiatives, and increased adoption of personalized rehabilitation protocols. Rising awareness of the long-term consequences of brain injuries, especially mild traumatic brain injuries (mTBIs), such as concussions, is playing a key role in catalyzing early intervention and boosting public engagement in prevention efforts. The increasing prevalence of TBIs among children and adolescents participating in organized sports is of particular concern. According to the CDC (2024), over two-thirds of concussions in high school sports are caused by athlete-to-athlete collisions, with baseball and basketball presenting especially high risks. Moreover, Stanford Children's Health reports that approximately 21% of the 3.5 million annual sports injuries among U.S. children are TBIs, underscoring the need for early diagnostic tools and tailored interventions for younger populations. Request Sample Pages: Epidemiological trends further emphasize the widespread impact of TBIs. Among adults aged 75 and older, falls account for 32% of TBI-related hospitalizations and 28% of deaths, while 81% of emergency visits in those over 65 are due to fall-related TBIs. Working-age adults (18–64 years) also carry a significant burden, mainly due to RTAs and occupational hazards. For instance, a 2020 study from Brazil analyzing 800 motor vehicle accident-related TBIs revealed a strong concentration among males in their 20s, highlighting gender- and age-related vulnerabilities. In children, nearly half of TBI emergency visits result from falls. Gender disparities are also prominent, with males experiencing nearly double the hospitalization rate of females. Market momentum is further bolstered by international research and funding commitments aimed at enhancing TBI care. A prime example is Australia's Traumatic Brain Injury Mission, launched under the Medical Research Future Fund (MRFF), which has allocated $50 million to support studies focused on recovery prediction and effective care models. Such initiatives catalyze the development of advanced tools for functional recovery assessment, predictive analytics, and AI-driven rehabilitation platforms. However, despite this optimistic outlook, the market continues to face significant restraints, most notably the high cost of treatment. The economic burden of TBI care, particularly in low- and middle-income countries (LMICs), limits access and poses barriers to widespread adoption of advanced therapies. In the U.S., treating a mild TBI can cost around $85,000, with moderate to severe cases reaching $900,000 to $3 million over a lifetime. Costs cover emergency care, imaging, hospitalization, and long-term rehabilitation. A single CT or MRI may cost $5,000–$8,000, while inpatient stays average $31,000. Rehabilitation is especially costly, with residential care at $1,000–$2,500 per day and physical therapy at $50–$250 per hour. These high costs strain healthcare systems, highlighting the urgent need for affordable, scalable TBI care solutions. Nevertheless, the future of the traumatic brain injury (TBI) treatment market remains promising. Driven by innovations in diagnostics, early intervention strategies, and support by public and private investment, the sector is rapidly transitioning toward more comprehensive and patient-centric approaches. Continued research into biomarkers for brain trauma, along with the adoption of personalized treatment protocols, is expected to improve outcomes and reduce long-term disabilities. As road traffic safety infrastructure improves in developing regions and awareness grows around the importance of helmet use and sports safety, incidence rates may stabilize. Therefore, the traumatic brain injury (TBI) treatment market is poised for transformative growth that could reshape neurological care and improve the lives of millions affected by traumatic brain injury. Market Forecast (2033) USD 4.7 billion CAGR 7.2% Top Driver Growing incidence of TBIs due to increasing sports injuries and road accidents Top Trend Rising Personalized & Targeted Therapies in Traumatic Brain Injury (TBI) Top Challenge High cost of treating traumatic brain injuries AI and ML Integration: Transforming TBI Diagnosis, Personalization, and Recovery Pathways The integration of artificial intelligence (AI) and machine learning (ML) into traumatic brain injury (TBI) care is redefining how clinicians diagnose, monitor, and treat brain trauma ushering in a new era of precision medicine and outcome-driven recovery strategies. Traditionally challenged by diagnostic variability and limited tools for predicting long-term effects, the TBI field is now being transformed by AI technologies that enable real-time imaging analysis, individualized treatment planning, and improved prognostic accuracy. A notable advancement lies in the deployment of AI-enhanced CT imaging and ML-based predictive models, currently under clinical investigation, which offer dynamic insights into injury progression and long-term functional outcomes. These tools help clinicians adapt rehabilitation protocols based on patient-specific risk factors, significantly improving the efficiency and effectiveness of care delivery. Technology companies and healthcare providers are forging strategic partnerships to accelerate the adoption of these tools, while research institutions continue to validate their clinical utility across diverse populations. These developments not only strengthen diagnostic precision and care quality but also reduce treatment costs, enhance patient monitoring, and open new frontiers in digital therapeutics. Global Traumatic Brain Injury (TBI) Treatment Market: Regional Trends Shaping the Future of Neurotrauma Care The global traumatic brain injury (TBI) treatment market is segmented into North America, South America, Europe, Asia-Pacific, and the Middle East & Africa, with North America retaining a leading position in 2024. The United States alone reports approximately one million emergency department visits for TBI each year, with over 230,000 hospitalizations and 80,000 individuals discharged with lasting disabilities, primarily due to road accidents and sports injuries. The region's dominance is supported by a well-established healthcare infrastructure, high healthcare expenditure, and strong uptake of advanced therapeutic technologies. Organizations such as the International Brain Injury Association (IBIA) and major academic trauma centers contribute significantly to clinical research, innovation, and patient support. Additionally, the availability of specialized rehabilitation programs and growing investments in neurotrauma care continue to support market expansion. Following North America, Europe holds a significant share of the global TBI treatment market, particularly led by countries like Germany, the United Kingdom, and France. A high incidence of fall-related TBIs, especially among the elderly, drives the demand for both acute care and long-term rehabilitation. Europe is advancing its position through initiatives such as the UK's TBI-REPORTER, a $12.61 million research project spearheaded by the University of Cambridge to consolidate patient data and accelerate treatment innovation. Robust public healthcare systems and integrated care pathways across the EU further enhance treatment accessibility and outcomes. The Asia-Pacific region is expected to witness the highest compound annual growth rate (CAGR) in the TBI treatment market. Rapid urbanization, rising road traffic injuries, and improving healthcare infrastructure in countries like China, India, Japan, and Australia are key growth drivers. Notably, Japan has approved AKUUGO, the world's first stem cell therapy for chronic TBI, signaling the country's leadership in treatment innovation. Meanwhile, China continues to invest heavily in TBI-related R&D in response to its high neurotrauma mortality rate of 13 per 100,000 people, aiming to improve early diagnosis and treatment accessibility. While growth in South America and the Middle East & Africa remains gradual, the outlook for market expansion is increasingly promising. In the MEA region, the rising incidence of road traffic injuries is driving government and private sector investments in trauma care infrastructure particularly in countries like the UAE and Saudi Arabia, where the development of specialized trauma centers is gaining momentum. Similarly, South America is witnessing early progress, fueled by public-private partnerships and growing awareness initiatives aimed at enhancing neurotrauma care. As healthcare infrastructure strengthens and supportive policies take shape, both regions are poised to play a more prominent role in shaping the global TBI treatment market in the years ahead. Recent Advancements and Key Players in the Traumatic Brain Injury (TBI) Treatment Market Several key players, including Cellvation, Oragenics, Oxeia Biopharmaceuticals, BioVie, Shinkei Therapeutics, Abliva/Owl Therapeutics, and other prominent companies, are at the forefront of innovation in the traumatic brain injury (TBI) treatment market. These organizations are driving progress through the development of novel therapeutics, advanced biologics, and regenerative medicine approaches aimed at improving patient outcomes and addressing unmet clinical needs in TBI care worldwide. For instance, in a significant advancement for TBI diagnostics, DRG Neuroscience (a division of DRG Instruments GmbH) announced the launch of its automated chemiluminescence immunoassay (CLIA) tests in January 2025. These rapid diagnostics, built on DRG's DxDATA platform, are designed to measure GFAP and UCH-L1 blood biomarker levels key indicators of brain injury within 30 minutes, provided samples are collected within 12 hours of suspected TBI occurrence. These tests are CE-marked and CLSI-verified, reflecting adherence to international standards and expanding accessibility to timely and accurate TBI diagnosis. On the therapeutic front, SanBio Inc. achieved a milestone with the July 2024 time-limited marketing approval in Japan for AKUUGO (Vandefitemcel), the world's first allogeneic bone marrow-derived mesenchymal stem cell therapy approved for chronic motor paralysis following traumatic brain injury. Approved for intracranial implantation, AKUUGO is based on promising outcomes from a global Phase II clinical trial and marks a transformative shift in the treatment of chronic TBI offering new hope for patients with limited recovery options. Modify Report as Per Requirements: Future Outlook: Advancing the Traumatic Brain Injury Treatment Market The traumatic brain injury (TBI) treatment market is poised for significant expansion, driven by ongoing innovations in neuro regenerative therapies, biomarker diagnostics, and personalized medicine. Rising global incidence of TBI, coupled with growing awareness and improved diagnostic capabilities, is creating substantial opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers to transform patient outcomes. Industry leaders anticipate accelerated development and regulatory approval of novel treatments including stem cell therapies, neuroprotective agents, and advanced surgical interventions that target the complex pathology of TBI. Cutting-edge technologies such as biomarker-driven diagnostics, artificial intelligence (AI)-enhanced imaging, and minimally invasive procedures are expected to streamline early diagnosis and optimize therapeutic strategies. The emergence of regenerative approaches, including mesenchymal stem cell therapies and gene-modified cellular treatments, holds promise in repairing neural damage and improving functional recovery in chronic TBI patients. Companies like Cellvation, Oragenics, and Shinkei Therapeutics are at the forefront of pioneering research and clinical trials, aiming to deliver transformative solutions across acute care and rehabilitation phases. Investment in infrastructure, such as specialized trauma centers and integrated rehabilitation programs, alongside government initiatives supporting neurotrauma research, will further catalyze market growth. Regulatory frameworks are evolving to facilitate faster approvals of breakthrough therapies, while reimbursement models are gradually adapting to cover innovative treatment modalities. By 2030, TBI treatments are expected to become more personalized, accessible, and integrated within multidisciplinary care pathways, fundamentally changing the prognosis for TBI patients worldwide. The convergence of advanced therapeutics, data-driven clinical decision-making, and scalable manufacturing will be crucial in overcoming current challenges. Continued exploration of allogeneic cell therapies and neuroprotective biologics promises to unlock new avenues for healing and functional restoration, shaping the future landscape of traumatic brain injury management. Key Competitors Cellvation Oragenics Oxeia Biopharmaceuticals BioVie Shinkei Therapeutics Abliva/Owl Therapeutics Other Prominent Players Segmentation of Amyotrophic Lateral Sclerosis Treatment Market By Treatment Type Medication Anti- seizures drugs Diuretics Pain relievers Antidepressant Stem Cell Therapy Surgery Others (Rehabilitation Therapies, Physiotherapy, etc) By Route of Administration Intravenous Oral Others By Distribution Channel Hospital & Rehabilitation Centres Pharmacies Retail Pharmacies Online Pharmacies By Region North America South America Europe Asia-Pacific Middle East and Africa Need More Info? Ask Before You Buy: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-06-2025
- Health
- Yahoo
Major Investment to Transform Mental Health Research
OTTAWA, ON, June 19, 2025 /CNW/ - Brain Canada is proud to announce its support for the development of the Brain Imaging Centre Advanced Multi-modal neuroimaging Platform for Psychiatry (BIC-AMPP) at The Royal Ottawa Health Care Group's BIC. Through its 2024 Platform Support Grants (PSG) program, Brain Canada is partnering with The Royal to invest $1.9 million in this groundbreaking initiative, which will integrate multiple brain imaging modalities to revolutionize mental health research. Led by Dr. Georg Northoff of the University of Ottawa's Institute of Mental Health Research (IMHR), the BIC-AMPP project brings together experts in MRI, PET, and EEG imaging to unlock the complex biochemical, structural, and functional changes associated with mental illness. This rare and technically advanced platform will allow researchers to simultaneously capture a more thorough and integrated picture of the brain, laying the groundwork for improved diagnostics and personalized treatments. "This investment represents a step-change in the capabilities of our team and our infrastructure, positioning Canada at the forefront of brain imaging research for mental health," said Dr. Florence Dzierszinski, President and CEO of the IMHR and vice-president of research at The Royal. "Simultaneous tri-modal imaging is only being actively pursued in two other centres in the world, yet offers endless possibilities with the right technology and skills." "This platform will enable us to link brain structure, chemistry, and function in real time," said Katie Dinelle, Administrative Director of The Royal's Clinical Brain Research Centre. "It will give us a more complete picture of mental illness and open new doors for discovery." "Mental health research has long been limited by our inability to fully understand how the brain's structure, chemistry, and function interact," said Dr. Georg Northoff, lead Principal Investigator for the BIC-AMPP. "By integrating multiple imaging modalities in a single platform, we can finally start to connect the dots. This will help us move beyond fragmented insights toward a more holistic understanding of mental illness—one that can inform better, more personalized treatments." The BIC-AMPP platform is designed to foster collaboration among scientists and provide unprecedented access to simultaneous multi-modal imaging, positioning The Royal as a hub for innovation and knowledge mobilization. Supported by expert scientific staff and a secure, open-access data-sharing infrastructure, the platform will accelerate discoveries that improve mental health care in Canada and beyond. Dr. Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of this initiative: "The BIC-AMPP represents a major leap forward in our ability to understand mental illness and develop personalized treatments. Brain Canada is proud to support this visionary platform, which underlines Canada's position as a global leader in brain imaging research." Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. "Research and innovation deepen our understanding, unlock new treatments, and improve quality of life for people affected by mental illness," said the Honourable Marjorie Michel, Minister of Health. "Through the Canada Brain Research Fund, the Government of Canada is pleased to support this initiative, bringing together experts from different fields to accelerate discoveries that will improve mental health care for Canadians." Over the coming weeks, Brain Canada will unveil the full list of 14 research platforms selected to receive PSG funding. The total investment of $36.8 million represents a major step forward in Canada's ability to support cutting-edge brain research and improve outcomes for people living with brain-disorders. For more information, please visit The Royal is one of Canada's foremost mental health care, teaching, and research hospitals and is home to the Royal Ottawa Mental Health Centre, the Brockville Mental Health Centre, the University of Ottawa Institute of Mental Health and the Royal Ottawa Foundation for Mental Health. Our mission is to transform the lives of people living with complex mental illness and addictions. Learn more about The Royal, our services, and our impact. SOURCE Brain Canada View original content to download multimedia:
The Australian
04-06-2025
- Business
- The Australian
Vital Signs: Compumedics
Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Gordon Haid, the Global Neuro-Imaging Business Director of Compumedics (ASX:CMP), a medical device company focused on diagnostic tech for sleep, brain and blood flow monitoring. Founded in 1987, Compumedics' strategy was initially focused on developing its core competency, Sleep Diagnostics. The company even set up Australia's first ever fully computerised sleep clinic. Today, Compumedics has evolved into one of the world's leading suppliers of medical technology for sleep, neuro diagnostics and ultrasonic blood flow monitoring, with products distributed to clients around the globe, helping millions of people who suffer from debilitating sleep, neurological and other healthcare problems. This podcast was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
Yahoo
19-05-2025
- Health
- Yahoo
Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer's Disease Care Through AI-Driven Imaging
SAN DIEGO, May 19, 2025 /PRNewswire/ -- a global leader in AI-driven neuroimaging solutions, today announced a strategic collaboration with the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) to enhance the quality of care for people living with Alzheimer's disease. This collaboration brings together advanced imaging platform, NeuroQuant® for ARIA, with ALZ-NET's robust real-world data network to help inform clinical decision-making, improve care delivery and contribute to future treatment guidelines. As part of the collaboration, discounted access to NeuroQuant® for ARIA will be offered to ALZ-NET sites across diverse clinical settings. NeuroQuant® for ARIA offers precise segmentation, quantification, and longitudinal tracking of both FLAIR and T2GRE/SWI lesions. This advanced functionality offers assistance with the surveillance of amyloid-related imaging abnormalities, such as ARIA-E and ARIA-H, in patients receiving anti-amyloid therapies. NeuroQuant® for ARIA is validated on both 2D and 3D FLAIR sequences, ensuring compatibility with a broad range of imaging protocols. NeuroQuant® for ARIA is the only clinically validated solution that detects and quantifies cerebral microbleeds and superficial siderosis on both T2GRE and SWI scans. Coupled with FLAIR lesion quantification of cerebral edema, NeuroQuant® for ARIA offers a complete solution for AI-assisted monitoring of Alzheimer's Disease patients on anti-amyloid immunotherapies. Dr. Ana Franceschi, a nationally recognized authority in dementia imaging and molecular neuroimaging and a member of both the Medical Advisory Board and ALZ-NET's Imaging Work Group, expressed strong support for the initiative: "It is a privilege to serve on Medical Advisory Board as we embark on this important collaboration with ALZ-NET. Combining advanced neuroimaging analytics with real-world data is a critical step in optimizing safety and monitoring for Alzheimer's patients receiving anti-amyloid therapies. This collaboration holds great promise for clinicians and patients alike." Sponsored by the Alzheimer's Association® and managed and operated by the American College of Radiology® (ACR®), ALZ-NET is a voluntary health care provider-enrolled network collecting real-world clinical and imaging data from patients evaluated for or treated with new FDA-approved Alzheimer's therapies Through the collection of longitudinal, real-world data across a multi-site network, ALZ-NET aims to provide evidence-based critical insights into long-term safety and efficacy of Alzheimer's therapies.. "Alzheimer's disease is a prevalent and devastating condition that touches millions of families. Our collaboration with ALZ-NET represents a shared commitment to using data and technology to improve how we care for people with dementia," says Kyle Frye, CEO of "With NeuroQuant® for ARIA, we're giving clinicians the tools they need to make smarter, safer decisions, and by connecting with ALZ-NET's powerful data network, we can collectively advance treatment practices for the entire field." For more information about visit and to learn more about or register to participate in ALZ-NET, visit or email About is a leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and early detection, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical device software that provides quantitative MR imaging analysis to assist clinicians in assessing neurodegeneration, as well as brain and prostate cancer. industry-leading imaging solutions offer radiologists, oncologists, and urologists a streamlined, cost-effective way to assess brain and prostate health, including cancer evaluation. The company also offers FDA-cleared products for evaluating neurological disorders such as Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma, tumors, and other brain abnormalities. For more information, please visit and follow us on Twitter, LinkedIn, and Facebook. For more information, please contact: info@ +1 858 459 970 View original content to download multimedia: SOURCE
News.com.au
14-05-2025
- Health
- News.com.au
Health Check: Compumedics claims world first ‘kids eat for free' brain scanning breakthrough
Compumedics' MEG unit can scan adult and kid's heads at the same time – a technically tricky task Microba's comprehensive gut testing reveals all is not well in the tummy region Trump's drug pricing blitz should be 'immaterial', says Telix Brain-scanning specialist Compumedics (ASX:CMP) reports a world's first: decent concurrent readings from both adult and children patients imaged by the same MEG device at China's Tianjin Normal University. It's like the old Smorgy's: kids eat for free. MEG stands for magnetoencephalography, a non-invasive neuroimaging technique that maps brain activity by recording magnetic fields produced by electrical currents in the grey matter. The problem to date is that the head scanners on MEGs haven't been compatible with young and adult noggins, which require two separate units. Many MEG measurements are done on kids, especially for epilepsy diagnostics. Compumedics' Orion Lifespan MEGs rectify this this with a two-scanner configuration (the scanner look like old-fashioned hair dryers at a salon). 'A key principle of MEG is that because magnetic fields drop off very rapidly with distance, the sensors should be as close as possible to the sources of the brain signals,' the company says. 'Since the sensors must be within a rigid helmet shape, a child's small head in an adult size helmet results in sensors far from the brain.' Orion Lifespan MEGs also enable better cooling – resulting in more sensitive measurements – and full recycling of the expensive coolant, liquid helium. This enables around-the-clock use of the units. Tianjin Normal University was the first of four Chinese institutions to buy an Orion MEG. In March this year Compumedics sold its fourth unit, to Hangzhou Normal University in a $5.7 million deal. The orders to date account for about $20 million of revenue. Compumedics founder and executive chair Dr David Burton says the company has spent 'many millions' over the last decade to perfect the units. Currently, about 200 MEGs are used globally. Burton reckons eventually there should be just as many MEGs as magnetic resonance imaging units – and there are 34,000 of the latter in use. Microba says we've all had a gutful An expansive study carried out by microbiome specialist Microba Life Sciences (ASX:MAP) suggests our tummies are not in the best of shape, but the ailments can be rectified with better clinical management. The company analysed 4600 patient results from its Metaxplore tests, which scan for 28,000 microbial species in the lower intestine. Some of these bugs are friendly and some of them are pathogenic. In more than 70% of cases, the preliminary results showed abnormalities in gut bacteria, signs of infection or inflammation markers "that could inform targeted treatment strategies". More than 42% of the tests showed microbiome markers linked to gastrointestinal health, while close to 10% exhibited symptoms such as inflammation, pancreatic insufficiency and blood in stools. Microba's selling point is that 65% of patients reported an improvement after following 'clinically directed recommendations informed by Metaxplore". The test can help clinicians to apply "personalised, multi-dimensional treatment plans to support the clinical management of patients with chronic and functional lower gastrointestinal disorders'. Even the tests identifying no problems can be helpful in terms of ruling out causes. In some cases, they may point to 'psychological or neurological contributors' to symptoms. In its March quarter update, Microba reported revenue of $3.4 million, down 14% . But management guided to full-year turnover of $15.25-16.25 million, 26-34% higher. Microba doubled sales of Metaxplore tests during the stanza, to 3225, taking the annualised run rate to 12,900 units. Locally the assays sell for $369 a pop. Telix shrugs off Trump drug pricing threat Telix Pharmaceuticals (ASX:TLX) has declared the Trump administration's proposed move to lower prescription drug prices has a 'a low likelihood of material impact' on the nuclear medicine group's business. The key reason is the unique nature of radiopharmaceuticals, which rely on a complex supply chain and 'just-in-time' manufacturing. In other words: the isotopes used on US patients need to be made in the US because of short half lives. The ready-to-inject radioactive doses are delivered through local nuclear pharmacy distributors. Under its most favoured nation decree, The Trump administration plans to benchmark local drug prices against those charged in the cheapest of the industrialised nations. The Prez claims this will reduce drug prices by up to 80% and save Medicare a poultice of money. But Telix says its localised production makes international pricing comparisons "challenging to benchmark". Telix derives most of its revenue in the US, from its approved prostate cancer imaging agent Illucix. The company intends to go ahead with commercialising kidney and brain cancer imaging products – Zircaix and Pixclara respectively – and advance cancer therapy agents. The company promises 'pharmaco-economically defensible' pricing in the US. Telix's comments were by way of a news item on its website, rather than an ASX announcement. OIL say! – that's a decent share rise Today's biotech winner is Optiscan (ASX:OIL), with its shares bounding three cents – 30% – in initial trade. Optiscan had nothing fresh to report, but yesterday said a robotic surgery development effort with Mayo Clinic was going well. Specifically, the venture is about incorporating Optiscan's digital confocal laser endomicroscopic (CLE) imaging in the robotic system. The robots do the fiddly work, while the surgeons guide via joystick (not even necessarily in the same room). The robots have a steadier hand – and often a better bedside manner. Rather than wait for biopsies, the CLE enables a real-time assessment in terms of cancer cell types and the extent of the margins at the edge of the tumour. 'This capability is expected to streamline surgical workflows, enhance decision-making, and reduce the likelihood of follow-up surgeries,' the company says. Optiscan CEO Dr Camile Farah says the venture – initially aimed at breast surgery – has 'materially progressed'.
